BH3:FRA
PTC Therapeutics, Inc.
55,00 €
arrow_downward
-0,61%(-0,34) 1D
9-окт., 22:00:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
55,00 €
High
55,00 €
Low
55,00 €
Mkt. cap
5,40 млд
Avg. vol.
0,00
Volume
0,00
52-wk high
77,02 €
52-wk low
52,50 €
No. of employees
991
Open
55,00 €
High
55,00 €
Low
55,00 €
Mkt. cap
5,40 млд
Avg. vol.
0,00
Volume
0,00
52-wk high
77,02 €
52-wk low
52,50 €
No. of employees
991
News stories
From web sources and news partners
MarketBeat
·
15 саат мурун
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Has Consensus Target Price of $98.25 According to Brokerages
Investing.com Canada
·
23 саат мурун
Form 4 PTC Therapeutics Inc For: 9 October By Investing.com
Stock Titan
·
1 күн мурун
Officer Mark Elliott Boulding proposes selling 192 shares of PTC Therapeutics (Nasdaq: PTCT).
Yahoo Finance
·
2 күн мурун
PTC Therapeutics, Inc. (PTCT) Stock Forecasts
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
Founded1998-ж., 1-янв.
HeadquartersУоррен, Нью Джерси, Америка Кошмо Штаттары
Sector-
Websiteptcbio.com